# A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod PH20 SC in Adults With Pemphigus (Vulgaris or Foliaceus)

> **NCT04598477** · PHASE3 · TERMINATED · sponsor: **argenx** · enrollment: 183 (actual)

## Conditions studied

- Pemphigus Vulgaris
- Pemphigus Foliaceus

## Interventions

- **BIOLOGICAL:** efgartigimod PH20 SC
- **DRUG:** prednisone

## Key facts

- **NCT ID:** NCT04598477
- **Lead sponsor:** argenx
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-07-15
- **Primary completion:** 2024-03-25
- **Final completion:** 2024-03-25
- **Target enrollment:** 183 (ACTUAL)
- **Why stopped:** Based on the lack of observed efficacy in the primary study ARGX-113-1904, the sponsor decided to discontinue the open-label extension study.
- **Last updated:** 2025-03-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04598477

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04598477, "A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod PH20 SC in Adults With Pemphigus (Vulgaris or Foliaceus)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04598477. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*